Resident Review Workshop

Thursday, October 17th

8:00 am – 12:00 pm

This workshop is sponsored by


Speaker #1:  Dr. David Vail, University of Wisconsin

Presentation Title: Cancer clinical trial design, implementation, and interpretation

Presentation Synopsis: This lecture will provide the tools necessary to understand and critically assess available clinical trial designs used at various stages of novel drug/technology development.  Further, a discussion of  the mechanistic details, potential obstacles, and the pros and cons of each approach will be presented through a review of cancer clinical trials currently published in the scientific literature.

About the Presenter:  Dr. Vail is currently Professor and Barbara A. Suran Chair in Comparative Oncology at the University of Wisconsin-Madison and a member of the UW Carbone Comprehensive Cancer Center.  Dr. Vail’s research involves the design and implementation of comparative oncology clinical trials through the inclusion of companion animal dogs and cats with spontaneous tumors. These spontaneous tumors have similar biological behavior as their counterparts in humans. The information obtained from these clinical trials help inform both the design of future trials in humans as well as provide preliminary data on ongoing drug development programs for animal health. Dr. Vail has published over 150 peer-reviewed scientific manuscripts and 50 book chapters in the field of veterinary and comparative oncology. David is co-editor of the textbook Small Animal Clinical Oncology.  He has served in the past as President of the Veterinary Cancer Society, Chairman of the Scientific Advisory Boards for both the Morris Animal Foundation and the American College of Veterinary Internal Medicine Foundation, President of the Canine Comparative Oncology and Genomics Consortium (CCOGC), and past North American journal editor for Veterinary and Comparative Oncology. He is a founding member of the Comparative Oncology Trials consortium.   He has been honored as the recipient of both the Mark L. Morris Sr. Distinguished Research Award and the Pfizer Award for Veterinary Research Excellence.

Speaker Notes:  David Vail Speaker Notes

 


Speaker #1:  Dr. Daniel Gustafson, Colorado State University

Presentation Topic:  Pharmacokinetic and pharmacodynamic considerations in cancer chemotherapy indications and dosing

Presentation Synopsis:  Drugs used for the treatment of animal cancers represent a diverse group of compounds with varying anti-tumor activities and side effects. Both the therapeutic and toxic activities of these agents in individual patients is based on pharmacokinetic (PK) and pharmacodynamic (PD) determinants that make up the subsequent pharmacologic response. PK determinants include absorption, distribution, metabolism and elimination (ADME) and PD determinants include target recognition, binding and transmission of tumor cell response. The discussion will focus on known PK and PD variability that alter drug response in specific individuals as well as highlighting specific agents and associated PK and PD traits. This review of cancer pharmacology will be agent specific and include indications and dosing defined by PK/PD.

About the Presenter:  Dr. Daniel L. Gustafson earned his bachelor’s degree in Biology from Santa Clara University and his PhD in Cell and Molecular Pharmacology and Physiology from the University of Nevada, Reno.  He completed his postdoctoral training in Radiation Biology and Pharmacology at Colorado State University & the University of Colorado Health Sciences Center. Dr. Gustafson spent eight years on the faculty at the University of Colorado Health Sciences Center where he founded the Pharmacology Shared Resource for the CU Cancer Center. He moved to the Flint Animal Cancer Center at Colorado State University in 2007 and currently serves as the Director of Basic Research for the FACC, the Director of the Pharmacology Shared Resource and co-Leader of Developmental Therapeutics for the CU Cancer Center and is the Shipley University Chair in Comparative Oncology. The focus of his research program is cancer therapeutics with a focus on pharmacokinetic and pharmacodynamic determinants of drug action and comparative aspects of these in pre-clinical and veterinary and human clinical oncology. He has been an author on over 140 original scientific articles in journals and over 100 abstracts presented at national and international conferences in the fields of cancer research and pharmacology.

Speaker Notes:  Daniel Gustafson Speaker Notes